Optigenex signs supply and trademark agreements with RFI

The agreement will allow RFI to market products under the registered trademark AC-11 and capitalize on the scientifically validated qualities of the patented AC-11 compound.

In third party preclinical and scientific studies, AC-11 has been shown to help the body’s natural ability to repair damage to DNA due to multiple causes, including the harmful effects of UV radiation from exposure to the sun, stress, toxins and environmental pollution, said Optigenex. Additional studies moreover have established the effectiveness of AC-11 as an inhibitor of pro-inflammatory agents, and as a natural immune stimulator, added Optigenex.

Jeff Wuagneux, president and CEO of RFI, said: “RFI and our sub-licensee GeneWize, a wholly owned subsidiary of GeneLink, are particularly enthusiastic about the present and future prospects related to AC-11 based formulas for distribution into the direct to healthcare practitioner channel under RFI’s PhytoRich brand as well as a primary component of the GeneWize direct selling genetic testing model, and we are fortunate to have aligned ourselves with a reputable science based company such as Optigenex.”

Daniel Zwiren, president and CEO of Optigenex, said: “The signing of these two agreements marks a significant milestone for Optigenex towards our goal of achieving brand awareness and continued validation of our technology through the adoption by market leaders. RFI has devoted significant time and resources in positioning AC-11 with a company that owns patented technology focused on targeting a unique supplement program based on a specific and personal genetic profile.”